Weight-loss version of smegalotide is officially launched in China
2024-11-17 02:48:14
Novo Nordisk announced on November 17 that Novo Yinying, the world's first and currently the only weekly preparation of glucagon-like peptide-1 receptor agonist (GLP-1) for long-term weight management, has been officially launched in China. Novo Yinying (smeglutide injection for long-term weight management) can achieve an average weight loss of about 17%, and its weight loss effect can last for at least 2 years. Up to now, smeglutide has accumulated more than 22 million years of experience in patients with exposure.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Trump allies tell Netanyahu: Do what you have to do to prevent Iran from getting nuclear weaponsNext article：
马斯克在财长竞选中支持卢特尼克反对贝森特
